Physiotherapy interventions for shoulder pain

S Green, R Buchbinder, S Hetrick, S Green, R Buchbinder, S Hetrick

Abstract

Background: The prevalence of shoulder disorders has been reported to range from seven to 36% of the population (Lundberg 1969) accounting for 1.2% of all General Practitioner encounters in Australia (Bridges Webb 1992). Substantial disability and significant morbidity can result from shoulder disorders. While many treatments have been employed in the treatment of shoulder disorders, few have been proven in randomised controlled trials. Physiotherapy is often the first line of management for shoulder pain and to date its efficacy has not been established. This review is one in a series of reviews of varying interventions for shoulder disorders, updated from an earlier Cochrane review of all interventions for shoulder disorder.

Objectives: To determine the efficacy of physiotherapy interventions for disorders resulting in pain, stiffness and/or disability of the shoulder.

Search strategy: MEDLINE, EMBASE, the Cochrane Clinical Trials Regiter and CINAHL were searched 1966 to June 2002. The Cochrane Musculoskeletal Review Group's search strategy was used and key words gained from previous reviews and all relevant articles were used as text terms in the search.

Selection criteria: Each identified study was assessed for possible inclusion by two independent reviewers. The determinants for inclusion were that the trial be of an intervention generally delivered by a physiotherapist, that treatment allocation was randomised; and that the study population be suffering from a shoulder disorder, excluding trauma and systemic inflammatory diseases such as rheumatoid arthritis.

Data collection and analysis: The methodological quality of the included trials was assessed by two independent reviewers according to a list of predetermined criteria, which were based on the PEDro scale specifically designed for the assessment of validity of trials of physiotherapy interventions. Outcome data was extracted and entered into Revman 4.1. Means and standard deviations for continuous outcomes and number of events for binary outcomes were extracted where available from the published reports. All standard errors of the mean were converted to standard deviation. For trials where the required data was not reported or not able to be calculated, further details were requested from first authors. If no further details were provided, the trial was included in the review and fully described, but not included in the meta-analysis. Results were presented for each diagnostic sub group (rotator cuff disease, adhesive capsulitis, anterior instability etc) and, where possible, combined in meta-analysis to give a treatment effect across all trials.

Main results: Twenty six trials met inclusion criteria. Methodological quality was variable and trial populations were generally small (median sample size = 48, range 14 to 180). Exercise was demonstrated to be effective in terms of short term recovery in rotator cuff disease (RR 7.74 (1.97, 30.32), and longer term benefit with respect to function (RR 2.45 (1.24, 4.86). Combining mobilisation with exercise resulted in additional benefit when compared to exercise alone for rotator cuff disease. Laser therapy was demonstrated to be more effective than placebo (RR 3.71 (1.89, 7.28) for adhesive capsulitis but not for rotator cuff tendinitis. Both ultrasound and pulsed electromagnetic field therapy resulted in improvement compared to placebo in pain in calcific tendinitis (RR 1.81 (1.26, 2.60) and RR 19 (1.16, 12.43) respectively). There is no evidence of the effect of ultrasound in shoulder pain (mixed diagnosis), adhesive capsulitis or rotator cuff tendinitis. When compared to exercises, ultrasound is of no additional benefit over and above exercise alone. There is some evidence that for rotator cuff disease, corticosteroid injections are superior to physiotherapy and no evidence that physiotherapy alone is of benefit for Adhesive Capsulitis

Reviewer's conclusions: The small sample sizes, variable methodological quality and heterogeneity in terms of population studied, physiotherapy intervention employed and length of follow up of randomised controlled trials of physiotherapy interventions results in little overall evidence to guide treatment. There is evidence to support the use of some interventions in specific and circumscribed cases. There is a need for trials of physiotherapy interventions for specific clinical conditions associated with shoulder pain, for shoulder pain where combinations of physiotherapy interventions, as well as, physiotherapy interventions as an adjunct to other, non physiotherapy interventions are compared. This is more reflective of current clinical practice. Trials should be adequately powered and address key methodological criteria such as allocation concealment and blinding of outcome assessor.

Conflict of interest statement

None known

Figures

1.1. Analysis
1.1. Analysis
Comparison 1 BIPOLAR INTERFERENTIAL CURRENT VERSUS PLACEBO, Outcome 1 Recovery or substantial improvement at 6 weeks.
1.2. Analysis
1.2. Analysis
Comparison 1 BIPOLAR INTERFERENTIAL CURRENT VERSUS PLACEBO, Outcome 2 Recovery or substantial improvement (participant rated) at 3 months.
1.3. Analysis
1.3. Analysis
Comparison 1 BIPOLAR INTERFERENTIAL CURRENT VERSUS PLACEBO, Outcome 3 Recovery or substantial improvement (participant rated) at 6 months.
1.4. Analysis
1.4. Analysis
Comparison 1 BIPOLAR INTERFERENTIAL CURRENT VERSUS PLACEBO, Outcome 4 Recovery or substantial improvement (participant rated) at 9 months.
1.5. Analysis
1.5. Analysis
Comparison 1 BIPOLAR INTERFERENTIAL CURRENT VERSUS PLACEBO, Outcome 5 Recovery or substantial improvement (participant rated) at 12 months.
2.1. Analysis
2.1. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 1 Recovery or substantial improvement (participant rated) ‐ short term.
2.2. Analysis
2.2. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 2 Recovery or substantial improvement (participant rated) at 3 months.
2.3. Analysis
2.3. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 3 Recovery or substantial improvement (participant rated) at 6 months.
2.4. Analysis
2.4. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 4 Recovery or substantial improvement (participant rated) at 9 months.
2.5. Analysis
2.5. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 5 Recovery or substantial improvement (participant rated) at 12 months.
2.6. Analysis
2.6. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 6 Resolution or improvement of radiological finding at end of treatment (6 weeks).
2.7. Analysis
2.7. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 7 Resolution or improvement of radiological finding at 9 months.
2.8. Analysis
2.8. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 8 Normal function at end of treatment (6 weeks).
2.9. Analysis
2.9. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 9 Normal function at 9 months.
2.10. Analysis
2.10. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 10 Change in range of flexion.
2.11. Analysis
2.11. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 11 Range of abduction.
2.12. Analysis
2.12. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 12 Change in internal rotation.
2.13. Analysis
2.13. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 13 Change in external rotation.
2.14. Analysis
2.14. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 14 Pain (100mmVAS) at 4 weeks.
2.15. Analysis
2.15. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 15 Painfree at 4 weeks.
2.16. Analysis
2.16. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 16 Pain (out of 20) at 4 months.
2.17. Analysis
2.17. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 17 Pain (out of 20) at 12 months.
2.18. Analysis
2.18. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 18 Function (out of 14) at 4 months.
2.19. Analysis
2.19. Analysis
Comparison 2 ULTRASOUND VERSUS PLACEBO, Outcome 19 Function (out of 14) at 12 months.
3.1. Analysis
3.1. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 1 Good or excellent function (Neer score) at 2 and a half years.
3.2. Analysis
3.2. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 2 No pain on activity at 2 and a half years.
3.3. Analysis
3.3. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 3 No pain at rest at 2 and a half years.
3.4. Analysis
3.4. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 4 No pain at night at two and a half years.
3.5. Analysis
3.5. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 5 Substantial improvement or recovered post treatment (1 month). Participant rated.
3.6. Analysis
3.6. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 6 No pain post treatment (1 month).
3.7. Analysis
3.7. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 7 Good or excellent function post treatment (1 month).
3.8. Analysis
3.8. Analysis
Comparison 3 SUPERVISED EXERCISES VERSUS PLACEBO OR NO TREATMENT, Outcome 8 Worsened range of abduction post treatment (1 month).
4.1. Analysis
4.1. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 1 Excellent or good result.
4.2. Analysis
4.2. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 2 Change in Range of Movement at four weeks.
4.3. Analysis
4.3. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 3 Change in night pain at four weeks.
4.4. Analysis
4.4. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 4 Change in pain at rest at four weeks.
4.5. Analysis
4.5. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 5 Change in pain on movement at four weeks.
4.6. Analysis
4.6. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 6 Change in function at four weeks.
4.7. Analysis
4.7. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 7 Change in range of movement at 8 weeks.
4.8. Analysis
4.8. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 8 Change in night pain at 8 weeks.
4.9. Analysis
4.9. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 9 Change in pain at rest at 8 weeks.
4.10. Analysis
4.10. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 10 Change in pain on movement at 8 weeks.
4.11. Analysis
4.11. Analysis
Comparison 4 LASER VERSUS PLACEBO, Outcome 11 Change in function at 8 weeks.
5.1. Analysis
5.1. Analysis
Comparison 5 PULSED ELECTROMAGNETIC FIELD VERSUS PLACEBO, Outcome 1 No pain at end of treatment (6 days).
5.2. Analysis
5.2. Analysis
Comparison 5 PULSED ELECTROMAGNETIC FIELD VERSUS PLACEBO, Outcome 2 No pain at 4‐6 Weeks.
5.3. Analysis
5.3. Analysis
Comparison 5 PULSED ELECTROMAGNETIC FIELD VERSUS PLACEBO, Outcome 3 Adverse effects.
6.1. Analysis
6.1. Analysis
Comparison 6 IONTOPHORESIS WITH ACETIC ACID PLUS ULTRASOUND VERSUS NO TREATMENT, Outcome 1 Percent change in size of calcium deposit.
6.2. Analysis
6.2. Analysis
Comparison 6 IONTOPHORESIS WITH ACETIC ACID PLUS ULTRASOUND VERSUS NO TREATMENT, Outcome 2 Percent improvement in abduction.
7.1. Analysis
7.1. Analysis
Comparison 7 BIPOLAR INTERFERENTIAL CURRENT VERSUS ULTRASOUND, Outcome 1 Recovery or substantial improvement (participant rated) at 6 weeks.
7.2. Analysis
7.2. Analysis
Comparison 7 BIPOLAR INTERFERENTIAL CURRENT VERSUS ULTRASOUND, Outcome 2 Recovery or substantial improvement (participant rated) at 3 months.
7.3. Analysis
7.3. Analysis
Comparison 7 BIPOLAR INTERFERENTIAL CURRENT VERSUS ULTRASOUND, Outcome 3 Recovery or substantial improvement (participant rated) at 6 months.
7.4. Analysis
7.4. Analysis
Comparison 7 BIPOLAR INTERFERENTIAL CURRENT VERSUS ULTRASOUND, Outcome 4 Recovery or substantial improvement (participant rated) at 9 months.
7.5. Analysis
7.5. Analysis
Comparison 7 BIPOLAR INTERFERENTIAL CURRENT VERSUS ULTRASOUND, Outcome 5 Recovery or substantial improvement (participant rated) at 12 months.
8.1. Analysis
8.1. Analysis
Comparison 8 TENS VERSUS ULTRASOUND, Outcome 1 Pain on VAS.
9.1. Analysis
9.1. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 1 Range of internal rotation at 3 to 4 weeks.
9.2. Analysis
9.2. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 2 Range of abduction at 3 to 4 weeks.
9.3. Analysis
9.3. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 3 Pain at 3 to 4 weeks.
9.4. Analysis
9.4. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 4 Range of passive abduction at 4 weeks.
9.5. Analysis
9.5. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 5 Composite strength score at 3 weeks.
9.6. Analysis
9.6. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 6 Function at 3 weeks.
9.7. Analysis
9.7. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 7 Pain on subacromial compression (mm on VAS) at 3 weeks.
9.8. Analysis
9.8. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 8 Range of elevation (degrees) at 3 weeks.
9.9. Analysis
9.9. Analysis
Comparison 9 MOBILISATION PLUS EXERCISE VERSUS EXERCISE ALONE, Outcome 9 Range of external rotation (degrees) at 3 weeks.
10.1. Analysis
10.1. Analysis
Comparison 10 MOBLISATION/ MANIPULATION VERSUS EXERCISES AND ELECTROTHERAPY, Outcome 1 Pain at end of intervention period.
10.2. Analysis
10.2. Analysis
Comparison 10 MOBLISATION/ MANIPULATION VERSUS EXERCISES AND ELECTROTHERAPY, Outcome 2 "Cured" at 5 weeks (participant rated).
10.3. Analysis
10.3. Analysis
Comparison 10 MOBLISATION/ MANIPULATION VERSUS EXERCISES AND ELECTROTHERAPY, Outcome 3 "Not cured" (participant rated) at 2 and a half years (in those followed up).
11.1. Analysis
11.1. Analysis
Comparison 11 ISOKINETIC RESISTANCE EXERCISES VERSUS ELECTROMYOGRAPHIC BIOFEEDBACK, Outcome 1 No functional limitation at work at 8 weeks.
11.2. Analysis
11.2. Analysis
Comparison 11 ISOKINETIC RESISTANCE EXERCISES VERSUS ELECTROMYOGRAPHIC BIOFEEDBACK, Outcome 2 No functional limitation at work at 26 weeks.
11.3. Analysis
11.3. Analysis
Comparison 11 ISOKINETIC RESISTANCE EXERCISES VERSUS ELECTROMYOGRAPHIC BIOFEEDBACK, Outcome 3 No functional limitation at work at 1 year.
11.4. Analysis
11.4. Analysis
Comparison 11 ISOKINETIC RESISTANCE EXERCISES VERSUS ELECTROMYOGRAPHIC BIOFEEDBACK, Outcome 4 No functional limitation at in sport at 8 weeks.
11.5. Analysis
11.5. Analysis
Comparison 11 ISOKINETIC RESISTANCE EXERCISES VERSUS ELECTROMYOGRAPHIC BIOFEEDBACK, Outcome 5 No functional limitation in sport at 26 weeks.
11.6. Analysis
11.6. Analysis
Comparison 11 ISOKINETIC RESISTANCE EXERCISES VERSUS ELECTROMYOGRAPHIC BIOFEEDBACK, Outcome 6 No functional limitation in sport at 1 year.
12.1. Analysis
12.1. Analysis
Comparison 12 PHYSIOTHERAPY WITH ELECTRO MAGNETIC THERAPY VERSUS PHYSIOTHERAPY WITH NO ELECTRO MAGNETIC THERAPY, Outcome 1 Range of shoulder flexion at 12 weeks.
12.2. Analysis
12.2. Analysis
Comparison 12 PHYSIOTHERAPY WITH ELECTRO MAGNETIC THERAPY VERSUS PHYSIOTHERAPY WITH NO ELECTRO MAGNETIC THERAPY, Outcome 2 Range of shoulder abduction at 12 weeks.
12.3. Analysis
12.3. Analysis
Comparison 12 PHYSIOTHERAPY WITH ELECTRO MAGNETIC THERAPY VERSUS PHYSIOTHERAPY WITH NO ELECTRO MAGNETIC THERAPY, Outcome 3 Range of shoulder external rotation at 12 weeks.
12.4. Analysis
12.4. Analysis
Comparison 12 PHYSIOTHERAPY WITH ELECTRO MAGNETIC THERAPY VERSUS PHYSIOTHERAPY WITH NO ELECTRO MAGNETIC THERAPY, Outcome 4 Range of shoulder internal rotation at 12 weeks.
12.5. Analysis
12.5. Analysis
Comparison 12 PHYSIOTHERAPY WITH ELECTRO MAGNETIC THERAPY VERSUS PHYSIOTHERAPY WITH NO ELECTRO MAGNETIC THERAPY, Outcome 5 Pain at rest at 12 weeks.
12.6. Analysis
12.6. Analysis
Comparison 12 PHYSIOTHERAPY WITH ELECTRO MAGNETIC THERAPY VERSUS PHYSIOTHERAPY WITH NO ELECTRO MAGNETIC THERAPY, Outcome 6 Pain on movement at 6 weeks.
12.7. Analysis
12.7. Analysis
Comparison 12 PHYSIOTHERAPY WITH ELECTRO MAGNETIC THERAPY VERSUS PHYSIOTHERAPY WITH NO ELECTRO MAGNETIC THERAPY, Outcome 7 Pain on lying at 6 weeks.
13.1. Analysis
13.1. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 1 Improvement in severity of main complaint at 3 weeks.
13.2. Analysis
13.2. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 2 Improvement in severity of main complaint at 7 weeks.
13.3. Analysis
13.3. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 3 Improvement in severity of main complaint at 13 weeks.
13.4. Analysis
13.4. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 4 Improvement in severity of main complaint at 26 weeks.
13.5. Analysis
13.5. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 5 Improvement in severity of main complaint at 52 weeks.
13.6. Analysis
13.6. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 6 Pain at 2‐3 weeks (100cm VAS).
13.7. Analysis
13.7. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 7 Improvement in severity of day pain at 7 weeks.
13.8. Analysis
13.8. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 8 Improvement in severity of day pain at 13 weeks.
13.9. Analysis
13.9. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 9 Improvement in severity of day pain at 26 weeks.
13.10. Analysis
13.10. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 10 Improvement in severity of day pain at 52 weeks.
13.11. Analysis
13.11. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 11 Improvement in severity of night pain at 3 weeks.
13.12. Analysis
13.12. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 12 Improvement in severity of night pain at 7 weeks.
13.13. Analysis
13.13. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 13 Improvement in severity of night pain at 13 weeks.
13.14. Analysis
13.14. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 14 Improvement in severity of night pain at 26 weeks.
13.15. Analysis
13.15. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 15 Improvement in severity of night pain at 52 weeks.
13.16. Analysis
13.16. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 16 Improvement in severity as rated by observer at 3 weeks.
13.17. Analysis
13.17. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 17 Improvement in severity as rated by observer at 7 weeks.
13.18. Analysis
13.18. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 18 Improvement in severity as rated by observer at 26 weeks.
13.19. Analysis
13.19. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 19 Improvement in rating of shoulder disability at 3 weeks.
13.20. Analysis
13.20. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 20 Improvement in rating of shoulder disability at 7 weeks.
13.21. Analysis
13.21. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 21 Improvement in rating of shoulder disability at 13 weeks.
13.22. Analysis
13.22. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 22 Improvement in rating of shoulder disability at 26 weeks.
13.23. Analysis
13.23. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 23 Improvement in rating of shoulder disability at 52 weeks.
13.24. Analysis
13.24. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 24 Range of abduction (degrees) at 2‐3 weeks.
13.25. Analysis
13.25. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 25 Improvement in degree of restriction of ROM of abduction at 7 weeks.
13.26. Analysis
13.26. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 26 Improvement in degree of restriction of ROM of abduction at 26 weeks.
13.27. Analysis
13.27. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 27 Improvement in degree of restriction of ROM of ER at 3 weeks.
13.28. Analysis
13.28. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 28 Improvement in degree of restriction of ROM of ER at 7 weeks.
13.29. Analysis
13.29. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 29 Improvement in degree of restriction of ROM of ER at 26 weeks.
13.30. Analysis
13.30. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 30 Number needing additional treatment at 7 weeks.
13.31. Analysis
13.31. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 31 Frequency of adverse reactions.
13.32. Analysis
13.32. Analysis
Comparison 13 INTRA‐ARTICULAR STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION, EXERCISE AND ELECTROTHERAPY), Outcome 32 Short term treatment success.
14.1. Analysis
14.1. Analysis
Comparison 14 INTRA‐ARTICULAR AND SUBACROMIAL STEROID INJECTION VERSUS PHYSIOTHERAPY (EXERCISES AND ELECTROTHERAPY), Outcome 1 Pain at end of intervention period.
14.2. Analysis
14.2. Analysis
Comparison 14 INTRA‐ARTICULAR AND SUBACROMIAL STEROID INJECTION VERSUS PHYSIOTHERAPY (EXERCISES AND ELECTROTHERAPY), Outcome 2 "Cured" at 5 weeks (participant rated).
14.3. Analysis
14.3. Analysis
Comparison 14 INTRA‐ARTICULAR AND SUBACROMIAL STEROID INJECTION VERSUS PHYSIOTHERAPY (EXERCISES AND ELECTROTHERAPY), Outcome 3 "Not cured" (participant rated) at 2 and a half years (in those followed up).
15.1. Analysis
15.1. Analysis
Comparison 15 INTRA‐ARTICULAR AND SUBACROMIAL STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION AND MANIPULATION), Outcome 1 Pain at end of intervention period.
15.2. Analysis
15.2. Analysis
Comparison 15 INTRA‐ARTICULAR AND SUBACROMIAL STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION AND MANIPULATION), Outcome 2 "Cured" at 5 weeks (participant rated).
15.3. Analysis
15.3. Analysis
Comparison 15 INTRA‐ARTICULAR AND SUBACROMIAL STEROID INJECTION VERSUS PHYSIOTHERAPY (MOBILISATION AND MANIPULATION), Outcome 3 "Not cured" (participant rated) at 2 and a half years (in those followed up).

Source: PubMed

3
Předplatit